NASDAQ:EWTX.O 14 January 2026

Edgewise Therapeutics stock jumps about 11% on 2026 trial calendar — what’s next for EWTX

Edgewise Therapeutics shares rose 10.6% to $27.59 by midday Wednesday after the company set timelines for key clinical trial readouts in muscle and heart diseases. Top-line data for Becker muscular dystrophy is expected in Q4 2026, with a U.S. drug application planned for early 2027. Investors are watching for Phase 2 and Phase 1 heart program results in the first half of 2026. Trading volume reached about 1 million shares.

14 January 2026

NASDAQ:EWTX.O·Pharmaceutical Industry·Stock Market

US Stocks, Bonds, and Gold Slide Amid Iran Conflict and Rising Oil Prices
March 20, 2026, 4:11 PM EDT. US stocks and bonds declined sharply as the Iran war intensified, pushing oil prices up and gold to its worst week in 40 years. The Russell 2000 index fell 2.7%, nearing correction territory (a 10% drop from peak). The Dow dropped 444 points (0.96%), S&P 500 fell 1.51%, Nasdaq slumped 2.01%, with the Nasdaq nearly in correction at down 9.65% since late October. The conflict raised energy prices, elevating inflation concerns and complicating central bank policies. Treasury yields surged, with the 10-year yield reaching 4.39%, the highest since July. Gold plunged 2% on Friday, marking a 10% weekly loss. Brent crude rose 3.26% to $112.19 per barrel. Market uncertainty persists over conflict duration and oil prices, with investors cautious about further downside.